RS50491B - Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja - Google Patents
Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenjaInfo
- Publication number
- RS50491B RS50491B YUP-979/02A YUP97902A RS50491B RS 50491 B RS50491 B RS 50491B YU P97902 A YUP97902 A YU P97902A RS 50491 B RS50491 B RS 50491B
- Authority
- RS
- Serbia
- Prior art keywords
- optionally substituted
- alkyl
- independently selected
- halogens
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 13
- 150000002367 halogens Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/38—TPC being performed in particular situations
- H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04B—TRANSMISSION
- H04B17/00—Monitoring; Testing
- H04B17/30—Monitoring; Testing of propagation channels
- H04B17/309—Measuring or estimating channel quality parameters
- H04B17/318—Received signal strength
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/02—Access restriction performed under specific conditions
- H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/06—TPC algorithms
- H04W52/14—Separate analysis of uplink or downlink
- H04W52/146—Uplink power control
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
- H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/20—Selecting an access point
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Computer Security & Cryptography (AREA)
- Quality & Reliability (AREA)
- Physics & Mathematics (AREA)
- Electromagnetism (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Steroid Compounds (AREA)
- Materials For Photolithography (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22068300P | 2000-07-25 | 2000-07-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU97902A YU97902A (sh) | 2006-05-25 |
| RS50491B true RS50491B (sr) | 2010-03-02 |
Family
ID=22824535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-979/02A RS50491B (sr) | 2000-07-25 | 2001-07-23 | Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6410583B1 (sr) |
| EP (1) | EP1305286B1 (sr) |
| JP (1) | JP4119745B2 (sr) |
| KR (1) | KR100746814B1 (sr) |
| CN (1) | CN1214007C (sr) |
| AT (1) | ATE284388T1 (sr) |
| AU (2) | AU2001277430B2 (sr) |
| BG (1) | BG66084B1 (sr) |
| BR (1) | BR0112756A (sr) |
| CA (1) | CA2416867C (sr) |
| CZ (1) | CZ2003236A3 (sr) |
| DE (1) | DE60107687T2 (sr) |
| DK (1) | DK1305286T3 (sr) |
| DZ (1) | DZ3402A1 (sr) |
| EA (1) | EA006765B1 (sr) |
| EC (1) | ECSP034428A (sr) |
| EE (1) | EE05287B1 (sr) |
| ES (1) | ES2231526T3 (sr) |
| GE (1) | GEP20053595B (sr) |
| HK (1) | HK1058934A1 (sr) |
| HR (1) | HRP20021039B1 (sr) |
| HU (1) | HUP0301745A3 (sr) |
| IL (2) | IL153406A0 (sr) |
| IS (1) | IS2170B (sr) |
| MX (1) | MXPA03000710A (sr) |
| NO (1) | NO325011B1 (sr) |
| NZ (1) | NZ523106A (sr) |
| PL (1) | PL207342B1 (sr) |
| PT (1) | PT1305286E (sr) |
| RS (1) | RS50491B (sr) |
| SK (1) | SK287507B6 (sr) |
| UA (1) | UA73787C2 (sr) |
| WO (1) | WO2002008186A2 (sr) |
| ZA (1) | ZA200300554B (sr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US7217725B2 (en) * | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| AR031200A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados |
| US6784172B2 (en) | 2000-11-03 | 2004-08-31 | Wyeth | Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| AR031197A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol |
| US6916922B2 (en) | 2000-11-03 | 2005-07-12 | Wyeth | Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives |
| US6858604B2 (en) | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| AU2002239463A1 (en) * | 2000-11-03 | 2002-06-03 | Wyeth | Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists |
| US6777407B2 (en) | 2000-11-03 | 2004-08-17 | Wyeth | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| TW200400963A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| TW200400818A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| EP1631547A1 (en) * | 2003-05-20 | 2006-03-08 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| JP2006527205A (ja) * | 2003-06-12 | 2006-11-30 | メルク フロスト カナダ リミテツド | Ｄｐ受容体拮抗物質としてのシクロアルカンピロロピリジン |
| ATE464048T1 (de) * | 2003-08-07 | 2010-04-15 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| EP1768674A1 (en) | 2004-07-16 | 2007-04-04 | ProteoSys AG | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| GT200500317A (es) | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| AU2006236939A1 (en) * | 2005-04-13 | 2006-10-26 | Merck Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| US7902177B2 (en) | 2005-05-02 | 2011-03-08 | Wandzel Richard A | Treatment of congestion using steroids and adrenergics |
| AR054849A1 (es) | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| WO2008097535A2 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
| NZ590474A (en) | 2008-07-23 | 2012-10-26 | Arena Pharm Inc | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS |
| CN102197038B (zh) | 2008-08-27 | 2016-04-20 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| MX2011003166A (es) * | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
| EP2387405A2 (en) | 2009-01-13 | 2011-11-23 | ProteoSys AG | Pirenzepine as an agent in cancer treatment |
| BR112012009808A2 (pt) | 2009-10-26 | 2015-09-29 | Bayer Cropscience Ag | nova forma sólida de 4-[[(6-cloropiridin - 3-il)metil]2,2-difluoroetil)amino] furan-2(5h)-ona |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| EP2542554B1 (en) | 2010-03-03 | 2015-11-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| US9797903B2 (en) | 2012-10-24 | 2017-10-24 | Winthrop-University Hospital | Non-invasive biomarker to identify subject at risk of preterm delivery |
| UA126268C2 (uk) | 2015-01-06 | 2022-09-14 | Арена Фармасьютікалз, Інк. | СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub> |
| EP3256121A1 (en) * | 2015-02-13 | 2017-12-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| EA201890096A1 (ru) | 2015-06-22 | 2018-08-31 | Арена Фармасьютикалз, Инк. | КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ |
| US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| KR20190113955A (ko) | 2017-02-16 | 2019-10-08 | 아레나 파마슈티칼스, 인크. | 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법 |
| WO2019055661A1 (en) | 2017-09-13 | 2019-03-21 | Progenity, Inc. | PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS |
| US11279656B2 (en) * | 2017-10-27 | 2022-03-22 | Applied Materials, Inc. | Nanopowders, nanoceramic materials and methods of making and use thereof |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN115260173A (zh) * | 2021-04-30 | 2022-11-01 | 厦门宝太生物科技股份有限公司 | 环戊烷并吲哚类支链酸衍生物及其制备方法和应用 |
| CN116854622A (zh) * | 2023-07-10 | 2023-10-10 | 青岛科技大学 | 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535326A (en) * | 1967-03-06 | 1970-10-20 | Sumitomo Chemical Co | Certain tetrahydro carboline derivatives |
| BE787444A (fr) | 1971-08-13 | 1973-02-12 | Hoffmann La Roche | Composes polycycliques |
| US4009181A (en) | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| US4057559A (en) | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
| ES2038653T3 (es) | 1986-01-23 | 1993-08-01 | Merck Frosst Canada Inc. | Acidos 1-alcanoicos tetrahidrocarbazol. |
| US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| US5221678A (en) | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| GB9101375D0 (en) | 1991-01-22 | 1991-03-06 | Erba Carlo Spa | N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole |
| MX9710256A (es) * | 1995-06-21 | 1998-03-31 | Shionogi & Co | Derivados de amino biciclicos y antagonistas pgd2 que contienen los mismos. |
| ES2181039T3 (es) * | 1996-12-13 | 2003-02-16 | Shionogi & Co | Derivados de benzotiofenocarboxamida y antagonistas de pgd2 que los comprenden. |
| CA2333868A1 (en) * | 1998-06-03 | 1999-12-09 | Shionogi & Co., Ltd. | Pharmaceutical compositions for the treatment of itching comprising pgd2 receptors antagonists |
-
2001
- 2001-07-20 US US09/909,636 patent/US6410583B1/en not_active Expired - Lifetime
- 2001-07-23 EP EP01955162A patent/EP1305286B1/en not_active Expired - Lifetime
- 2001-07-23 GE GE5105A patent/GEP20053595B/en unknown
- 2001-07-23 DZ DZ013402A patent/DZ3402A1/fr active
- 2001-07-23 AU AU2001277430A patent/AU2001277430B2/en not_active Expired
- 2001-07-23 KR KR1020037001117A patent/KR100746814B1/ko active IP Right Grant
- 2001-07-23 CA CA002416867A patent/CA2416867C/en not_active Expired - Fee Related
- 2001-07-23 WO PCT/CA2001/001069 patent/WO2002008186A2/en active IP Right Grant
- 2001-07-23 MX MXPA03000710A patent/MXPA03000710A/es active IP Right Grant
- 2001-07-23 RS YUP-979/02A patent/RS50491B/sr unknown
- 2001-07-23 EE EEP200300033A patent/EE05287B1/xx not_active IP Right Cessation
- 2001-07-23 CN CNB018131662A patent/CN1214007C/zh not_active Expired - Fee Related
- 2001-07-23 CZ CZ2003236A patent/CZ2003236A3/cs unknown
- 2001-07-23 PT PT01955162T patent/PT1305286E/pt unknown
- 2001-07-23 DE DE60107687T patent/DE60107687T2/de not_active Expired - Lifetime
- 2001-07-23 SK SK93-2003A patent/SK287507B6/sk not_active IP Right Cessation
- 2001-07-23 BR BR0112756-0A patent/BR0112756A/pt active Search and Examination
- 2001-07-23 EA EA200300171A patent/EA006765B1/ru not_active IP Right Cessation
- 2001-07-23 AU AU7743001A patent/AU7743001A/xx active Pending
- 2001-07-23 AT AT01955162T patent/ATE284388T1/de active
- 2001-07-23 ES ES01955162T patent/ES2231526T3/es not_active Expired - Lifetime
- 2001-07-23 UA UA2003021565A patent/UA73787C2/uk unknown
- 2001-07-23 IL IL15340601A patent/IL153406A0/xx active IP Right Grant
- 2001-07-23 NZ NZ523106A patent/NZ523106A/en not_active IP Right Cessation
- 2001-07-23 JP JP2002514093A patent/JP4119745B2/ja not_active Expired - Fee Related
- 2001-07-23 HU HU0301745A patent/HUP0301745A3/hu unknown
- 2001-07-23 PL PL363168A patent/PL207342B1/pl not_active IP Right Cessation
- 2001-07-23 DK DK01955162T patent/DK1305286T3/da active
-
2002
- 2002-12-12 IS IS6655A patent/IS2170B/is unknown
- 2002-12-12 IL IL153406A patent/IL153406A/en not_active IP Right Cessation
- 2002-12-30 HR HR20021039A patent/HRP20021039B1/xx not_active IP Right Cessation
-
2003
- 2003-01-06 BG BG107438A patent/BG66084B1/bg unknown
- 2003-01-13 EC EC2003004428A patent/ECSP034428A/es unknown
- 2003-01-21 ZA ZA200300554A patent/ZA200300554B/en unknown
- 2003-01-24 NO NO20030374A patent/NO325011B1/no not_active IP Right Cessation
-
2004
- 2004-03-11 HK HK04101796A patent/HK1058934A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS50491B (sr) | Ciklopentanoindoli, smeše koje sadrže takva jedinjenja i metodi lečenja | |
| RS49586B (sr) | Derivati supstituisane 4-hidroksi-fenilalkanske kiseline sa dejstvom agonista na ppar-gama | |
| RS52134B (sr) | Modulatori receptora glukokortikoida | |
| RS50454B (sr) | Derivati 2-okso-1-pirolidina, postupak njihovog dobijanja i njihove upotrebe | |
| HRP20030003B1 (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
| RS50519B (sr) | Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona | |
| HRP20021023B1 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| YU68896A (sh) | Jedinjenja hinolina i nihazolina od koristi u terapiji | |
| RS51650B (sr) | Kinuklidinski derivati (hetero) arilcikloheptankarboksilne kiseline kao antagonisti muskarinskog receptora | |
| HRP20080431T3 (en) | Novel dicarboxylic acid derivatives | |
| DE69316377D1 (de) | Serotoninrezeptor-mittel | |
| HRP20070529T3 (en) | Imidazole derivatives as glutmate receptor antagonists | |
| RS50893B (sr) | Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora | |
| CO4771153A1 (es) | Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p. | |
| TW200604185A (en) | Chemical compounds | |
| DK351788A (da) | Tetrahydroisoquinolin-2-ylderivater af carboxylsyrer som thromboxan-a2-antagonister | |
| YU71496A (en) | Azetidines, their salts, application and process for preparation | |
| HUP9903758A2 (hu) | Benzoxazinon dopamin D4 receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények | |
| DK0874841T3 (da) | 1-Benzensulfonylpyrrolidin-derivater som antagonister af bradykinin-receptoren | |
| ATE5141T1 (de) | Xanthon- und thioxanthonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| RS51320B (sr) | Derivati imidazohinolina kao veznici a3 receptora adenozina | |
| AR037211A1 (es) | Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1 | |
| HK1050532A1 (en) | Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same | |
| YU47605B (sh) | Postupak za dobijanje supstituisanih derivata stirena |